Global Metastatic Colorectal Cancer Market to 2030 - Insight, Epidemiology and Forecasts - ResearchAndMarkets.com

The "Metastatic Colorectal Cancer Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Metastatic Colorectal Cancer (mCRC) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident Population of Colorectal Cancer, and Incident Population of Metastatic Colorectal Cancer (mCRC) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.

Metastatic Colorectal Cancer (mCRC) Drug Chapters

The drug chapter segment of the Metastatic Colorectal Cancer (mCRC) report encloses the detailed analysis of Metastatic Colorectal Cancer (mCRC) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Metastatic Colorectal Cancer (mCRC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Metastatic Colorectal Cancer (mCRC) Market Outlook

Colorectal cancer (CRC) is the second most frequent type of cancer that represents approximately 12 - 14% of all cancer cases in men and women. Out of these, approximately 25% of patients present with metastases at initial diagnosis and almost 50% may eventually develop metastases, contributing to the high mortality rates reported for CRC. In order to identify the optimal treatment strategy for patients with mCRC, tumor staging is essential and should include at least clinical examination, blood counts, liver and renal function tests, CEA, and CT scan of the abdomen and chest (or alternatively MRI).

The treatment plan may include a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, which can be used to slow the spread of the disease and often temporarily shrink a cancerous tumor. Palliative care is also important to help relieve symptoms and side effects.

The first, second, and third-line treatment regimen of mCRC involves the use of multi-agent chemotherapy (i.e. FOLFOX, FOLFIRI, CAPEOX), anti-angiogenesis therapy with or without chemotherapy, epidermal growth factor receptor (EGFR) inhibitors with or without chemotherapy, and others with or without chemotherapy. Along with these therapies, Opdivo, with or without Yervoy, and Braftovi, in combination with Erbitux, are approved for the treatment of mCRC patients as the only second and third-line therapies, while Keytruda is approved as the only first-line therapy of mCRC.

Key Findings

• The Metastatic Colorectal Cancer market size in the 7MM is expected to change during the study period 2018 - 2030, at a CAGR of 2.9%. According to the estimates, the highest market size of mCRC is accessed in the United States followed by Japan, in 2020.
• The United States Market Outlook - This section provides the total Metastatic Colorectal Cancer (mCRC) market size and market size by therapies in the United States.
• EU-5 Market Outlook - The total Metastatic Colorectal Cancer (mCRC) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
• Japan Market Outlook - The total Metastatic Colorectal Cancer (mCRC) market size and market size by therapies in Japan are provided.

Report Highlights

• In the coming years, mCRC market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence mCRC R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• The publisher analysed specific data of mCRC, which suggests that the incidence of mCRC is anticipated to decline during the forecast period.
• Currently, the first, second and third-line treatment regimen of mCRC involves the use of multiagent chemotherapy (i.e. FOLFOX, FOLFIRI, CAPEOX), anti-angiogenesis therapy with or without chemotherapy, Epidermal growth factor receptor (EGFR) inhibitors with or without chemotherapy, Keytruda, Opdivo with or without Yervoy, Braftovi in combination with
• Erbitux and others with chemotherapy.
• The market space of mCRC would benefitted in the coming years with the launch of several emerging therapies. These therapies include triplet combination of Braftovi + Mektovi + Erbitux, Modufolin (arfolitixorin) + bevacizumab, Adagrasib, Lumakras (sotorasib) + panitumumab, Elunate (fruquintinib), Tukysa (tucatinib) Herceptin (trastuzumab), Onvansertib.

Companies Mentioned

• Merck
• Alexion Pharmaceuticals
• GlaxoSmithKline (GSK)
• Array BioPharma
• Pfizer
• Eli Lilly
• Taiho Oncology
• Bristol-Myers Squibb
• Amgen
• Mirati Therapeutics
• Hutchison Medipharma
• G1 Therapeutics
• Eisai
• Isofol Medical
• AB Science
• Incyte Corporation
• Daiichi Sankyo
• AstraZeneca
• Cardiff oncology
• EpicentRx
• Seagen
• Black Diamond Therapeutics
• Gilead Sciences

For more information about this report visit https://www.researchandmarkets.com/r/apcqsc

View source version on businesswire.com: https://www.businesswire.com/news/home/20220117005487/en/

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900